GB2438834A — Intranasal protein administration
Assigned to Optinose AS · Expires 2007-12-12 · 18y expired
What this patent protects
Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins, to the upper posterior region of a nasal cavity of a subject is achieved using a delivery device comprising a housing 15, a nosepiece 20 with nozzle 25, and a mouthpi…
USPTO Abstract
Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins, to the upper posterior region of a nasal cavity of a subject is achieved using a delivery device comprising a housing 15, a nosepiece 20 with nozzle 25, and a mouthpiece 19 through which the subject exhales to actuate the delivery device. Upon actuation, an administered protein formulation is delivered to the olfactory bulb region (OB, figure 1) where it is taken up into the central nervous system. In this manner, delivery of the protein formulation to the nasal associated lymphatic tissue is avoided in order to prevent a neutralising antibody response.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.